Osteoporosis requires bone-specific statins

Current Pharmaceutical Design

Volumn 10, Issue 21, 2004, Pages 2605-2613

  Koida, Masao ^a   Fukuyama, Ryo ^b   Nakamuta, Hiromichi ^b  

^a SETSUNAN UNIVERSITY   (Japan)

^b HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

BMP 2; Bone anabolic effect; Osteoblast; Osteoclast; Osteoporosis; Runx2 Cbfa1; Small GTPases; Statins

Indexed keywords

ALENDRONIC ACID; ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CALCITONIN; CALCIUM; CERIVASTATIN; COMPACTIN; ESTROGEN; ESTROGEN DERIVATIVE; FLUINDOSTATIN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PITAVASTATIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; STRONTIUM; VITAMIN D; VITAMIN D DERIVATIVE;

ADIPOCYTE; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE MINERALIZATION; BONE STRUCTURE; CALCIUM TRANSPORT; CELL TYPE; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; ENZYME INHIBITION; FRAGILITY FRACTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE DEVELOPMENT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OSTEOPOROSIS;

EID: 3242883083     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383827     Document Type: Review

References (62)

1. Khosla S, Melton III J, Atkinson EJ, O'Fallen WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocr Metab 2001; 86: 3555-61.
2. Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res 2002; 57: 385-409.
3. Adachi JD, Ioannidis G, Pickard L, Berger C, Prior JC, Joseph L, et al. The association between osteoporotic fractures and health-related quality of life as measured by the health utilities index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporosis Int 2003; 14: 895-904.
4. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporosis Int 2000; 11: 556-61.
5. Hauselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporosis Int 2003; 14: 2-12.
6. Takai Y, Sasaki T, Matozaki T. Small GTP-binidng proteins. Physiol Rev 2001; 81: 153-208.
7. Coxon FP, Rogers MJ. file role of prenylated small GTP-binding proteins in the regulation of osteoclast function. Calcif Tssue Int 2003; 72: 80-4.
8. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by penicillum citrinum. J Antibiotics 1976; 29: 1346-9.
9. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994; 344: 1383-1389.
10. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of statins on risk of coronary disease. JAMA 1999; 282: 2340-23.
11. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946-1949.
12. Sakou T. Bone morphogenetic proteins: from basic studies to clinical approaches. Bone 1998; 22: 591-603.
13. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Harris F, et al. Statin use, bone mass and fracture: an analysis of two prospective studies. J Bone Miner Res 1999; 14(Suppl): S179.
14. Bauer DC. HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporosis Int 2003; 14: 273-282.
15. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, et al. Use of statins and fracture - Results of 4 prospective studies and Cumulative meta-analysis of observation studies and controlled trials. Arch Intern Med 2004; 164: 146-52.
16. Chan KA, Andrade SE, Boles M, Buist DSM, Chase GA, Donallue JG, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355: 2185-8.
17. Pedersen TR, Kjekshus J. 4S Study Group. Statin drugs and the risk of fracture. JAMA 2000; 284: 1921-2.
18. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H: HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205-10.
19. van Staa T, Wegman S, de Vries F, Leufkens B, Cooper C: Use of statins and risk of fractures. JAMA 2001; 285: 1850-5.
20. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000; 283: 3211-6.
21. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. Statin use, bone mineral density, and fracture risk: Geelong osteoporosis study. Arch Intern Med 2002; 162: 537-40.
22. Barengolts E, Karanouh D, Kolodny L, Kukreja S: Risk factors for hip fractures in predominantly African-American veteran male population. J Bone Miner Res 2001; 16(Suppl): S170.
23. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, et al. Effect of pravastatin on frequency of fracture in the LIPID study:secondary analysis of a randomized controlled trial. Lancet 2 001; 357: 509-12.
24. LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med 2003; 139: 97-104.
25. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T. Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 2001; 110: 584-7.
26. Montagnani A, Gonnelli S, Cepollaro C, Pacini S, Campagna MS, Franci MB, et al. Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study. Bone 2003; 32: 427-433.
27. Chung Y-S, Lee M-D, Lee S-K, Kim H-M, Fitzpatrick LA. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocr Metab 2000; 85: 1137-42.
28. Edwards CJ, Hart D, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000; 355: 2218-9.
29. Solomon DH, Finkelstein JS, Wang PS, Avorn J. Statin lipid-lowering drugs and bone density. J Bone Miner Res 2001; 16(Suppl): S293.
30. Rejnmark L, Buus NH, Vestergaard P, Andreasen E, Larsen ML, Mosekilde L. Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest 2002; 32: 581-589.
31. Sirola J, Honkanen R, Kroger H, Jurvelin JS, Maenpaa P, Saarikoski S. Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporosis Int 2002; 13: 537-41.
32. Wada Y, Nakamura Y, Koshiyama H. Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med 2000; 160: 2865.
33. Oxlund H, Dalstra M, Andreassen TT. Statin given perorally to adult rats increases cancellous bone mass and compressive strength. Calcif Tissue Int 2001; 69: 299-304.
34. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents: Arterioscler Thromb Vasc Biol 2001; 21: 1636-41.
35. Skoglund B, Forslund C, Aspenberg P. Simvastatin improves fracture healing in mice. J Bone Miner Res 2002; 17: 2004-8.
36. von Stechow D, Fish S, Yahalom D, Bab I, Chorev M, Muller R, et al. Does simvastatin stimulate bone formation in vivo? BMC Musculoskeletal disorders; 2003; 4: 8.
37. Ohno T, Shigetomi M, Ihara K, Matsunaga T, Hashimoto T, Kawano H, et al. Skeletal reconstruction by vascularized allogenic bone transplantation: effects of statin in rats. Transplantation 2003; 76: 869-71.
38. Staal A, Frith JC, French MH, Swartz J, Gungor T, Harrity TW, et al. The ability of statins to inhibit bone resorption is direcely related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 2003; 18: 88-96.
39. Guitierrez G, Garrett IR, Rossini G, Castano M, Chapa G, Escobedo A, et al. Dermal application of lovastatin to rats causes greater increases in bone formation and plasma concentrations than when administered by oral gavage. J Bone Miner Res 2000; 15 (Suppl): S427.
40. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, and Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Common 2000; 271: 688-92.
41. Maeda T, Matsunuma A, Kawane T, and Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 2001; 280: 874-7.
42. Ohnaka K, Shimoda S, Nawata H, Shimokawa H, Kaibuchi K, Iwamoto Y, et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun 2001; 287: 337-42.
43. Izumo N, Fujita T, Nakamuta H, Koida M. Lipophilic statins can be osteogenic by promoting osteoblastic calcification in a Cbfa1- and BMP-2-independent manner. Methods Find Exp Clin Pharmacol 2001; 23: 389-94.
44. Song C, Guo Z, Ma Q, Chen Z, Liu Z, Jia H, Dang G. Simvastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells. Biochem Biophys Res Commun 2003; 308: 458-62.
45. Fukuyama R, Fujita T, Azuma Y, Hirano A, Nakamuta H, Koida M, et al. Statins inhibit osteoblast migration by inhibiting Rac-Akt signaling. Biochem Biophys Res Commun. 2004; 315: 636-42.
46. Fukuyama R. a doctoral dissertation from Setsunan University. 2004
47. Woo J, Kasai S, Stern PH, Nagai K. Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts. J Bone Miner Res 2000; 15: 650-62.
48. Staal A, Frith J, French MH, Swartz J, Gungor T, Harrity TW, et al. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 2003; 18: 88-96.
49. Komori Y, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89: 755-764.
50. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblastic differentiation and bone formation. Cell 2002; 108: 17-29.
51. Kato Y, Windle JJ, Koop BA, Mundy GR, Bonewald. Establishment of an osteocytic cell line, MLO-Y4. J Bone Miner Res 1997; 12: 2014-23.
52. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, et al. Reversal of bone loss in mice by non-genotropic signaling of sex steroids. Science 2002; 298: 843-6.
53. Fujita T, Meguro T, Fukuyama R, Nakamuta H, Koida M. New signaling pathway for parathyroid hormone and cyclic AMP action on extracellular-regulated kinase and cell proliferation in bone cells. J Biol Chem 2002; 277: 22191-22200.
54. Masuda N, Akasaka I, Suzuki J, Fujino A, Ohtawa M, Nakaya N, et al. Phase I study of fluvastatin, a new syntheitc HMG-CoA reductase Inhibitor. Pharmacokinetics of fluvastatin in healthy volunteers after single and multiple oral administration. Rinshouiyaku 1995; 11(Suppl): 65-81.
55. Oishi S, Watanabe T, Higuchi S, Hiraku A, Omura K, Matsumura M, et al. Atorvastatin (CL-981) clinical pharmacokinetic study (V): Pharmacokinetics of single dose atorvastatin in healthy young and elderly volunteers. Jpn Pharmacol Ther 1998; 26: 1295-305.
56. Ohtawa M, Uchiyama N, Saito Y, Suzuki A, Tanno C: Phase I study of MK-733 in healthy subjects after single and multiple oral administration. II: Pharmacokinetics of MK-735 in healthy subjects after single and multiple oral administration. J Clin Ther Med 1989; 5: 1123-1140.
57. Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1990; 1045: 112-20.
58. Lian JB, Stein GS, Aubin JE. In: Favus MJ Ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington DC, American Society for Bone and Mineral Metabolism 2003; pp13-28.
59. Cauley, JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. JAMA 2003; 290: 1729-38.
60. Carbonin P, Zuccala G, Marzetti E, Lo Monaco MR. Coronary risk factors in the elderly: their interactions and treatment. Curr Pharm Design 2003; 9(29): 2465-78.
61. Lian JB, Stein GS. Runx2/Cbfa1: a multifunctional regulator of bone formation. Curr Pharm Design 2003; 9(32): 2677-85.
62. Reginster JY. Strontium ranelate in osteoporosis. Curr Pharm Design 2002; 8(21): 1907-16.